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Abstract 46 
 47 
Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-48 
inflammatory processes, with many of these effects attributed to FFAs interacting 49 
with a family of G protein-coupled receptors.  Selective synthetic ligands for Free 50 
Fatty Acid receptors (FFA1-4) have consequently been developed as potential 51 
treatments for type 2 diabetes (T2D).  In particular, clinical studies show that 52 
Fasiglifam, an agonist of the long chain FFA receptor, FFA1, improved glycaemic 53 
control and reduced HbA1c levels in T2D patients, with a reduced risk of 54 
hypoglycemia. However, this ligand was removed from clinical trials due to potential 55 
liver toxicity and determining if this is a target or a ligand-specific feature is now of 56 
major importance. Pre-clinical studies also show that FFA4 agonism increases insulin 57 
sensitivity, induces weight loss and reduces inflammation and the metabolic and anti-58 
inflammatory effects of short chain fatty acids (SCFAs) are linked with FFA2 and 59 
FFA3 activation. In this review, we therefore show that FFA receptor agonism is a 60 
potential clinical target for T2D treatment and discuss ongoing drug development 61 
programmes within industry and academia aimed at improving the safety and 62 
effectiveness of these potential treatments.   63 
 64 
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 95 
Introduction 96 
 97 
In 2013, 382 million people worldwide were characterised as diabetics with around 98 
90% of patients diagnosed with type 2 diabetes (T2D), a metabolic disorder 99 
intrinsically linked with obesity (Alberti and Zimmet, 2014). T2D is defined by 100 
insulin resistance in peripheral tissues, such as the liver and muscle, and a loss of 101 
pancreatic beta-cell function, resulting in insufficient insulin secretion (McCarthy, 102 
2010) and constitutes a risk factor for health issues including cardiovascular disease, 103 
impaired wound healing, blindness, and renal failure (Alberti and Zimmet, 2014). 104 
Although T2D can sometimes be controlled through strict diet regulation, a large 105 
number of patients require clinical therapies. Current treatments, such as metformin, 106 
sulfonylureas, glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl 107 
peptidase-4 (DPP-4) inhibitors, are deployed primarily to either improve insulin 108 
secretion, peripheral insulin sensitivity or both (Majumdar and Inzucchi, 2013). 109 
However, there remains a demand for distinct, safe and effective treatments for T2D, 110 
with the current therapies often associated with side effects including hypoglycemia 111 
and weight gain. Naturally occurring free fatty acids (FFAs) found in the diet, 112 
including ω-3 fatty acids, have profound effects on metabolic and inflammatory 113 
processes associated with T2D, although the molecular basis for these effects are 114 
complex and incompletely understood (Offermanns, 2014). FFAs are classified based 115 
upon their chain length, such that short chain fatty acids (SCFAs) have 1-6 carbon 116 
atoms; medium chain fatty acids (MCFAs) contains 7-12 carbon atoms and long-117 
chain fatty acids (LCFAs) contain more than 12 carbon atoms (Offermanns, 2014). 118 
Many of the biological effects of FFAs have now been attributed, at least in part, to 119 
FFAs interacting with a group of G protein-coupled receptors (GPCRs) designated the 120 
FFA receptors.  The most well characterised FFA receptors are the two LCFA-121 
specific receptors, FFA1 and FFA4, and the SCFA-specific receptors FFA2 and FFA3. 122 
FFA receptor agonism, particularly of the FFA1 receptor, has subsequently been 123 
shown to have beneficial metabolic effects (Offermanns, 2014). Consequently, a 124 
number of ongoing industrial and academic programmes are focused upon developing 125 
potent and selective synthetic agonists of FFA1. Although currently less developed, 126 
activation of each of FFA2, FFA3 and FFA4 has also been suggested to have potential 127 
benefits for metabolic function. In this review, we will therefore discuss the potential 128 
of FFA receptor agonists as novel clinical treatments for T2D. 129 
 130 
FFA1 131 
 132 
FFA1, activated by various saturated (e.g. palmitic acid, C16:0), mono-unsaturated 133 
(e.g. oleic acid, C18:1) and polyunsaturated long chain FFAs (e.g. linoleic acid, 134 
C18:2) (Table 1), is a Gq/11-coupled GPCR predominantly expressed in pancreatic 135 
beta cells, that is associated with increased glucose-stimulated insulin secretion 136 
(GSIS) (Offermanns, 2014, Ferdaoussi et al., 2012, Latour et al., 2007) (Figure 1). 137 
FFA1 is also expressed by various enteroendocrine cells where it regulates the release 138 
of incretin hormones such as glucagon-like peptide-1 (GLP-1), an insulinotropic, 139 
anorectic peptide that reduces gastric emptying and motility, as well as 140 
cholecystokinin (CCK), shown to regulate pancreatic secretion, inhibit gastric motility 141 
and reduce energy intake (Houze et al., 2012, Luo et al., 2012, Liou et al., 2011, 142 
Edfalk et al., 2008) (Figure 1). FFA1 is also present within the central nervous system 143 
(CNS) (Nakamoto et al., 2013, Ma et al., 2007) although whether neuronal FFA1 144 
contributes to the regulation of glucose homeostasis remains to be fully determined 145 
(Figure 1). FFA1 expression has also been reported in glucagon-producing alpha cells 146 
within the pancreas, although this remains controversial (Flodgren et al., 2007, Wang 147 
et al., 2011, Itoh et al., 2003, Lan et al., 2008, Hirasawa et al., 2008). FFA1 148 
expression has also been well characterised in taste buds where it mediates, in part, 149 
taste preference for fatty acids, although the significance of this, and possible effects 150 
of pharmacological activation or blockade, remains to be fully elucidated (Cartoni et 151 
al., 2010, Gilbertson and Khan, 2014) (Figure 1). 152 
 153 
FFA1 and insulin secretion 154 
 155 
Acute FFA-mediated insulin secretion from isolated human and rodent islets involves 156 
amplification of the second phase of GSIS (Latour et al., 2007, Ferdaoussi et al., 2012, 157 
Kebede et al., 2012, Itoh et al., 2003). This is reduced by approximately 50% in 158 
FFA1-null mice, with the remaining effect attributed to intracellular metabolism of 159 
FFAs (Latour et al., 2007, Ferdaoussi et al., 2012, Kebede et al., 2012, Itoh et al., 160 
2003). In contrast, transgenic overexpression of FFA1 under the control of the mouse 161 
insulin II promoter prevents development of hyperglycemia and improves insulin 162 
secretion and glucose tolerance in diabetic mouse models (Nagasumi et al., 2009). As 163 
anticipated from this, GW9508, a synthetic FFA1 agonist (Table 1), stimulated GSIS 164 
in pancreatic MIN6 cells (Briscoe et al., 2006). FFA1 gene expression is also reduced 165 
under glucolipotoxic conditions in rats and in islets from T2D patients whilst a rare 166 
mutation in the human FFA1 gene is associated with attenuated lipid-mediated 167 
enhancement of GSIS (Del Guerra et al., 2010, Fontes et al., 2010, Walker et al., 168 
2011). The effects of FFA1 on pancreatic beta cell viability, however, has been 169 
controversial, with pancreatic-specific FFA1 overexpression associated with disrupted 170 
islet morphology and impaired beta cell function whereas FFA1 disruption is linked 171 
with increased beta cell viability in mice fed on a High Fat Diet (HFD)(Steneberg et 172 
al., 2005). These observations promoted the concept that, at least in the longer term, 173 
FFA1 antagonism could be beneficial in the treatment of diabetes. However, most 174 
subsequent preclinical studies contradict these findings, indicating that FFA1 agonism 175 
has no detrimental effects on beta cell viability (Nagasumi et al., 2009, Kebede et al., 176 
2012, Lan et al., 2008), or even protects beta cells (Zhang et al., 2007, Wu et al., 2010, 177 
Wagner et al., 2013).  178 
 179 
The FFA1 agonist Fasiglifam and insulin secretion 180 
 181 
Although there are currently no FFA1 agonists approved for clinical use, considerable 182 
interest developed around Fasiglifam (designated TAK-875 in pre-clinical studies, 183 
Figure 2), an orally available FFA1 agonist developed by Takeda (Yashiro et al., 2012, 184 
Tsujihata et al., 2011, Araki et al., 2012) (Table 1). Completed Phase II clinical trials 185 
demonstrated that T2D patients treated with Fasiglifam had reduced blood glucose 186 
levels, increased insulin levels and resulted in a 1.2–1.4% reduction in haemoglobin 187 
A1c (HbA1c) levels (Mancini and Poitout, 2013, Burant et al., 2012, Naik et al., 2012, 188 
Araki et al., 2012, Leifke et al., 2012) (Table 1). Crucially, although these effects 189 
were comparable to current sulfonylurea treatments, Fasiglifam was associated with 190 
markedly less side effects, with no significant increases in body weight and a reduced 191 
concomitant incidence of hypoglycaemia (Mancini and Poitout, 2013, Burant et al., 192 
2012, Naik et al., 2012, Araki et al., 2012, Leifke et al., 2012). This is consistent with 193 
pre-clinical data demonstrating that Fasiglifam improved fasting hyperglycemia and 194 
glucose tolerance and augmented GSIS in diabetic rat models, with no hypoglycaemia 195 
observed in normoglycemic rats (Tsujihata et al., 2011). No changes in insulin 196 
resistance have been reported in response to Fasiglifam treatment (Burant, 2013, 197 
Bailey, 2012) and Fasiglifam had no effect on glucagon secretion in isolated human 198 
islets and did not alter glucagon levels in T2D patients (Poitout and Lin, 2013). 199 
Importantly, prolonged Fasiglifam exposure was also not associated with beta cell 200 
dysfunction or apoptosis (Tsujihata et al., 2011).    201 
 202 
The effect of partial vs. full FFA1 agonists on incretin release from 203 
enteroendocrine cells 204 
 205 
The ability of synthetic FFA1 agonists to induce significant incretin release was 206 
recently shown to depend upon whether the compound was a partial or full agonist 207 
(Luo et al., 2012, Edfalk et al., 2008, Lin et al., 2012a) (Figure 1). In this regard, 208 
TAK-875/Fasiglifam had no effect on incretin release from enteroendocrine cells with 209 
similar results reported for AMG-837 (Amgen, Table 1, Figure 2) (Poitout and Lin, 210 
2013). In contrast, Amgen described AM-1638 and AM-5262 (Table 1, Figure 2) as 211 
full FFA1 agonists that directly stimulate insulin secretion and promote incretin 212 
release from enteroendocrine cells (Brown et al., 2012, Wang et al., 2013, Poitout and 213 
Lin, 2013) (Figure 1). This incretin-stimulating effect was abolished in FFA1 214 
knockout mice and the effect of AM-1638 on glucose homeostasis was attenuated by 215 
the GLP-1R antagonist, Ex(9–39)NH2, indicating a particularly key role for GLP-1 216 
(Poitout and Lin, 2013). Similarly, LY2881835, a full FFA1 agonist from Eli Lilly 217 
(Table 1), increased GSIS, lowered blood glucose levels and increased GLP-1 218 
secretion in animal models (Defossa and Wagner, 2014). Amgen demonstrated that 219 
multiple ligand binding pockets exist on FFA1, comprising of up to two allosteric 220 
sites as well as the FFA binding orthosteric site (Lin et al., 2012a). One allosteric site 221 
is targeted by compounds such as AM-837 and TAK-875 whilst the second allosteric 222 
site is a target for receptor agonists such as AM-1638 that act as full agonists. 223 
Consequently, positive co-operativity was shown between either AMG-837 or AM-224 
1638 in conjunction with natural FFA ligands in cell based assays measuring second-225 
messenger generation, as well as primary cell based assays, with positive co-226 
operativity also reported between AMG-837 and AM-1638 during an oral glucose 227 
tolerance test in a diabetic rodent model (Lin et al., 2012a) 228 
 229 
FFA1 agonists: Ongoing FFA1 drug programmes and future challenges 230 
 231 
Although no issues were raised regarding safety and tolerability during Phase I and II 232 
trials, Fasiglifam was recently withdrawn from phase III trials due to potential liver 233 
toxicity (Defossa and Wagner, 2014) (Table 1). Similarly, Amgen and Eli Lilly 234 
removed AMG-837 and LY2881835 (Table 1, Figure 2) respectively from Phase I 235 
clinical trials due to concerns over toxicity (Defossa and Wagner, 2014). However, 236 
the preclinical and clinical data generated using Fasiglifam provides a strong rationale 237 
and validation for further studies into the potential use of FFA1 agonism as a novel 238 
treatment for T2D. Currently, Japan Tobacco are conducting Phase II clinical trials 239 
with their FFA1 agonist candidate, JTT-851 and Piramal have begun Phase I clinical 240 
trials on their FFA1 agonist, P11187 (Defossa and Wagner, 2014) (Table 1). Daiichi 241 
Sanyko also recently described 3-aryl-3-ethoxypropanoic acids as orally active FFA1 242 
agonists that improve insulin secretion and glucose homeostasis in rats (Takano et al., 243 
2014). Additionally, FFA1 agonists developed by Astellas are reported to have 244 
beneficial effects on glucose homeostasis in diabetic mouse models (Tanaka et al., 245 
2014, Tanaka et al., 2013). Sanofi and Boehringer-Ingelheim are also reported to have 246 
FFA1 agonist programmes under development (Defossa and Wagner, 2014). In an 247 
academic context, the University of Southern Denmark have developed 4-248 
(benzylamine)hydrocinnamic acid FFA1 agonists such as TUG-469 (Christiansen et 249 
al., 2010, Christiansen et al., 2012) and 4-alkynehydrocinnamic acid FFA1 agonists, 250 
including TUG-424, and TUG-770 (Christiansen et al., 2013b, Christiansen et al., 251 
2008, Urban et al., 2013) (Table 1). Within these programmes, several strategies have 252 
been followed to reduce compound lipophilicity (Christiansen et al., 2011, 253 
Christiansen et al., 2012, Christiansen et al., 2013a). Consequently, TUG-770 (Figure 254 
2) has recently been described as a highly potent FFA1 agonist with favourable 255 
physicochemical and pharmacokinetic properties, improving glucose tolerance in diet-256 
induced obese mice. This effect did not desensitise, being fully maintained after 29 257 
days of chronic dosing (Christiansen et al., 2013b).  258 
 259 
FFA4 260 
 261 
FFA4, a Gq-coupled GPCR activated by LCFAs, including α-linolenic acid (α-LA) 262 
and docosahexaenoic acid (DHA) (Table 1), is expressed in enteroendocrine cells, 263 
lung, brain, white adipose tissues, heart and liver (Offermanns, 2014). Within adipose 264 
tissue, FFA4 gene expression is upregulated following a HFD and FFA4 activation in 265 
adipocytes is associated with increased adipogenesis and glucose uptake (Cornall et 266 
al., 2014, Hudson et al., 2013b, Oh et al., 2010), suggesting that FFA4 activation may 267 
promote adiposity and obesity (Figure 1). However, mutation of FFA4 (p.R270H 268 
variant) is associated with an increased risk of obesity in European populations, 269 
(although this variant is almost absent in a Japanese population) and young FFA4 null 270 
mice fed a HFD gained significantly more fat mass than their wild-type littermates, 271 
suggesting that FFA4 protects against diet-induced obesity (Ichimura et al., 2012).  272 
FFA4 agonism is also commonly associated with improved insulin sensitivity, with 273 
FFA4 null mice reported to have increased fasting glucose and impaired responses to 274 
insulin and glucose tolerance testing (Ichimura et al., 2012, Oh et al., 2010) (Figure 1).  275 
A number of these metabolic effects, such as increased insulin secretion, satiety, and 276 
improved glycemic control, have been attributed, at least in part, to FFA4-dependent 277 
incretin release from enteroendocrine cells, particularly GLP-1 (Hirasawa et al., 2005, 278 
Cornall et al., 2014, Offermanns, 2014, Hudson et al., 2013b) (Figure 1). GLP-1 279 
secretion was demonstrated both in vitro and in vivo using aLA as an agonist 280 
(Hirasawa et al., 2005). Similarly, TUG-891 (Figure 2), a potent FFA4 agonist (see 281 
below), also increased GLP-1 secretion from STC-1 and GLUTag enteroendocrine 282 
cells (Hudson et al., 2013b). However, a recent study has questioned the significance 283 
of FFA4-mediated GLP-1 release (Paulsen et al., 2014). FFA4 also co-localises with 284 
the orexigenic peptide, ghrelin, in duodenal cells in vivo, with recent studies showing 285 
that FFA4 activation inhibits ghrelin secretion (Engelstoft et al., 2013, Gong et al., 286 
2014). An emerging role for FFA4 within pancreatic islets has also recently 287 
developed, with the pancreatic islets of diabetic and hyperglycaemic individuals 288 
shown to have decreased levels of FFA4 mRNA and knockdown of FFA4 mRNA 289 
levels within islets demonstrated to attenuate the protective effects of the ω-3 fatty 290 
acid, eicosapentaenoic acid against palmitate-induced cell apoptosis (Taneera et al., 291 
2012) (Figure 1). FFA4 expression has also recently been detected in delta cells and 292 
alpha cells within the pancreas and was consequently linked with the inhibition of 293 
glucose-dependent somatostatin release and the regulation of glucagon secretion 294 
respectively (Stone et al., 2014, Suckow et al., 2014) (Figure 1). Similar to FFA1, 295 
FFA4 is also expressed in taste buds and is linked with the regulation of taste 296 
preference although, again, the significance of this in relation to obesity and T2D 297 
remains to be clarified (Abdoul-Azize et al., 2014) (Figure 1).    298 
 299 
The anti-inflammatory effects of FFA4 300 
  301 
A recent study indicated that, in addition to the previously described insulin-302 
sensitising effects associated with GLP-1 release, improved systemic insulin 303 
sensitivity may also be associated with FFA4-mediated anti-inflammatory effects on 304 
macrophages (Oh et al., 2010) (Figure 1). In this study, FFA4 expression in 305 
macrophages was elevated in response to obesity and FFA4 activation decreased pro-306 
inflammatory gene expression in M1 macrophages and increased expression of M2 307 
anti-inflammatory genes with reduced macrophage infiltration of adipose tissues also 308 
observed in FFA4 null mice due to decreased chemotaxis (Oh et al., 2010). These 309 
anti-inflammatory effects are largely associated with FFA4-mediated recruitment of 310 
beta-arrestin 2, a scaffold protein typically associated with receptor desensitisation 311 
and internalisation that is also implicated in the regulation of distinct signalling 312 
pathways (Oh et al., 2010, Halder et al., 2013, Li et al., 2013). In the case of FFA4, 313 
beta-arrestin 2 interacts with TAB1 that, in turn, inhibits lipopolysaccharide (LPS)- 314 
and tumour necrosis factor (TNF)-alpha-induced TAK1 stimulation, thereby blocking 315 
toll-like receptor 4 (TLR4) and the TNF-alpha inflammatory pathways (Oh et al., 316 
2010, Halder et al., 2013, Li et al., 2013). Interestingly, recent studies have also 317 
reported FFA4-mediated anti-inflammatory effects within the brain. In particular, 318 
FFA4 has been associated with the anti-inflammatory effects of ω-3 and ω-9 fatty 319 
acids in the hypothalamus, thereby reducing diet-induced inflammation and reducing 320 
body adiposity (Cintra et al., 2012, Wellhauser and Belsham, 2014) (Figure 1). 321 
 322 
Synthetic FFA4 agonists 323 
 324 
Initial synthetic FFA4 agonists, including GW9508, NCG21 (Figure 2) and NCG46 325 
(Table 1), showed significant dual agonism at FFA1 (Holliday et al., 2011). However, 326 
our groups have recently reported on TUG-891, a potent and selective FFA4 agonist 327 
(Hudson et al., 2013b, Shimpukade et al., 2012) (Table 1, Figure 2), although TUG-328 
891 is significantly less selective for murine FFA4 compared to murine FFA1, 329 
potentially limiting its use in preclinical in vivo studies in mice (Shimpukade et al., 330 
2012). Recent modelling and mutational efforts have, however, clearly defined how 331 
TUG-891 interacts with FFA4 (Hudson et al., 2014b), information that will be 332 
invaluable in developing novel ligands with improved pharmacological properties for 333 
this receptor. To date, no FFA4 agonists have entered clinical trials although a 334 
number of FFA4 agonist programmes are ongoing. For example, Banyu 335 
Pharmaceutical Co. Ltd, IRM LLC USA, Metabolex, Inc, Kindex Therapeutics, and 336 
Pharma Frontier Co. Ltd have all patented FFA4 agonists for the treatment of 337 
metabolic and inflammatory disease (Halder et al., 2013) (Table 1). Similarly, GSK 338 
has recently described a series of diarylsulfonamides as FFA4 agonists (Sparks et al., 339 
2014) and Metabolex has reported that their series of dihydrobenzofuran-based FFA4 340 
agonists improved glucose homeostasis in mice, with moderate glucose-lowering 341 
effects in mice shown with a separate series of FFA4 agonists (Halder et al., 2013). 342 
Additionally, Kindex Therapeutics described beneficial effects in the treatment of 343 
obesity, inflammation, and metabolic disorders with alpha acids that were reported to 344 
act both as FFA4 agonists and also as partial PPARγ agonists (Halder et al., 2013).   345 
 346 
Metabolic regulation by FFA2 and FFA3 347 
 348 
High fibre intake protects against obesity and T2D via SCFA production, particularly 349 
butyrate, acetate and propionate, from bacterial fermentation of dietary fibre in the 350 
large intestine (Cani et al., 2013). Moreover, modulation of gut microbiota using pre- 351 
and probiotics in both mice and humans regulates body weight, appetite and glucose 352 
homeostasis (Cani et al., 2013). These SCFA-mediated beneficial effects on body 353 
weight and glucose homeostasis in HFD-fed mice are due, at least in part, to 354 
FFA2/FFA3-dependent mechanisms, including for example increased secretion of 355 
incretins, such as GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and 356 
peptide YY (PYY) (Nohr et al., 2013, Cani et al., 2013). These receptors are activated 357 
by the SCFAs produced by fibre fermentation in the gut, with the human FFA2 358 
orthologue preferentially activated by shorter SCFAs, such as acetate, whereas human 359 
FFA3 is activated preferentially by the longer SCFAs, with propionate being the most 360 
potent SCFA for both receptors, at least in human (Offermanns, 2014, Cani et al., 361 
2013, Nohr et al., 2013, Tolhurst et al., 2012, Brown et al., 2003, Le Poul et al., 2003, 362 
Nilsson et al., 2003, Schmidt et al., 2011) (Table 1, Figure 1). However, the relative 363 
potency and preference for various SCFAs appears to vary significantly across species 364 
(Hudson et al., 2012a, Hudson et al., 2012b). SCFA-triggered secretion of GLP-1 was 365 
almost completely abolished in primary colonic cultures from FFA2 null mice and 366 
reduced, to a lesser extent, in mice lacking FFA3 (Tolhurst et al., 2012). FFA2 is 367 
expressed in adipose tissue, intestine, islet cells, enteroendocrine cells and immune 368 
cells whilst FFA3 is highly expressed in the small intestine, colon, and pancreas 369 
(Offermanns, 2014). FFA2 expression levels are also elevated in the skeletal muscle, 370 
liver, and adipose tissue of HFD-fed rodents, with FFA2 shown to regulate 371 
adipogenesis and adipocyte differentiation and inhibit lipolysis (Bindels et al., 2013) 372 
(Figure 1). 373 
 374 
Complete elucidation of the metabolic effects of FFA2 and FFA3 has, however, been 375 
complicated by conflicting results using FFA2 and FFA3 null mice. For example, in 376 
one study, HFD-fed FFA2 null mice display lower body fat mass and improved 377 
glucose control compared to wild type mice, indicating a role for FFA2 antagonists in 378 
the treatment of T2D (Bjursell et al., 2011). Contrastingly, FFA2 null mice were also 379 
shown to be obese on a normal diet, with reduced insulin sensitivity and marked 380 
insulin resistance whereas adipocyte-specific overexpression of FFA2 resulted in 381 
lower body weight in a HFD study (Kimura et al., 2013). Similarly, the loss of FFA3 382 
either resulted in weight loss, obesity or had no effect in different studies (Zaibi et al., 383 
2010, Samuel et al., 2008, Lin et al., 2012b). Hence, the development of more potent 384 
and selective FFA2 and FFA3 agonists will hopefully facilitate the elucidation of the 385 
metabolic effects of FFA2 and FFA3 and ultimately provide future treatments for 386 
T2D. Several selective compound series are already known, especially for FFA2 387 
(Ulven, 2012) (Table 1). Small carboxylic acids derived from the natural SCFA 388 
ligands have shown appreciable and predictable selectivity but have low potency 389 
(Schmidt et al., 2011). Selective allosteric agonists of FFA2 were reported by Amgen 390 
to regulate lipolysis (eg. AMG7703/4-CMTB, Table 1, Figure 2). However, the 391 
clinical use of these drugs was deemed to be limited due to low solubility and poor 392 
pharmacokinetics (Wang et al., 2010). Orthosteric FFA2 agonists and antagonists 393 
have also now been reported (Hudson et al., 2012b, Hudson et al., 2013a) and used to 394 
demonstrate a role for this receptor in improved glucose uptake, decreased colon 395 
motility and contractility, increased GLP-1 secretion and inhibiting leukocyte 396 
activation (Cornall et al., 2013, Ulven, 2012, Hudson et al., 2012a, Hudson et al., 397 
2012b). FFA3 agonists are even less developed although Arena Pharmaceuticals has 398 
reported a series of FFA3-selective compounds (Ulven, 2012) (Table 1). 399 
Pharmacological characterisation of compounds from this series demonstrated that 400 
individual members have diverse pharmacological properties, acting as intrinsic 401 
agonists and/or allosterically modulating the potency or efficacy of the response to 402 
SCFA propionate (Hudson et al., 2014a). Hence, although recent microbiota studies 403 
highlight quite elegantly the role that gut-derived SCFAs can play in the regulation of 404 
metabolism, there still remains a great demand for improved FFA2 and FFA3 agonists 405 
to fully unravel and define the consequences of activation of these receptors for 406 
metabolic health.   407 
 408 
Future perspectives 409 
 410 
The withdrawal of FFA1 agonists from clinical trials, particularly Fasiglifam, 411 
highlights the critical importance of establishing whether the adverse effects reported 412 
during these clinical trials are due to FFA1 agonism or the chemical structures of the 413 
particular FFA1 agonists. Additionally, as FFA2, FFA3 and FFA4 agonists further 414 
develop and hopefully enter clinical trials, it will be interesting to see if the same 415 
issues highlighted during FFA1 trials will also arise. Future research should also fully 416 
address the relative effects of partial and full FFA1 agonists, particularly in relation to 417 
allosterism in conjunction with natural FFA ligands. Additionally, dual agonists of 418 
FFA1 and FFA4 may have enhanced effects on insulin secretion and insulin 419 
sensitivity compared to selective FFA1 or FFA4 agonists alone. Similarly, co-420 
therapeutic approaches involving FFA receptor agonists and current T2D therapies 421 
should be examined. For example, the FFA1 agonist, AS2575959 (Table 1), acts 422 
synergistically with a DPP-IV inhibitor to improve glucose homeostasis (Tanaka et al., 423 
2014) and combination therapy with Fasiglifam and metformin displayed enhanced 424 
anti-diabetic effects in a diabetic rat model (Ito et al., 2013). Similarly, the FFA1 425 
agonist, DS-1558 (Table 1), acts synergistically with exendin-4, a GLP-1 receptor 426 
agonist, to improve glucose homeostasis in diabetic mice (Nakashima et al., 2014). 427 
Clearly, there are a number of significant challenges ahead in the development of 428 
clinical treatments based on FFA receptor agonism. However, should these challenges 429 
be met, FFA receptor agonism may provide a novel and effective way to treat T2D.  430 
 431 
Non-standard Abbreviations  432 
 433 
T2D, type 2 diabetes; GLP-1, glucagon-like peptide-1; DPP-4, dipeptidyl peptidase-4; 434 
FFA, free fatty acid, FFA1-4, Free Fatty Acid Receptors 1-4; SCFA, short chain fatty 435 
acid; MCFA, medium chain fatty acid; LCFA, long chain fatty acid; GPCR, G 436 
protein-coupled receptor; GSIS, glucose-stimulated insulin secretion; CNS, central 437 
nervous system; HFD, high fat diet; HbA1c, haemoglobin A1c; aLA, α linoleic acid, 438 
DHA, docosahexaenoic acid; LPS, lipopolysaccharide; TNF, tumour necrosis factor; 439 
PYY, peptide YY; GIP, glucose-dependent insulinotropic polypeptide  440 
 441 
Acknowledgements 442 
 443 
This work is supported in part by grants from the Biotechnology and Biosciences 444 
Research Council [BB/K019864/1] (to G.M), a Canadian Institutes of Health 445 
Research (fellowship to B.D.H.) and the Danish Council for Strategic Research grant 446 
[11-116196] (to T.U. and G.M.). 447 
 448 
Conflict of interest statement 449 
 450 
None 451 
 452 
References 453 
 454 
ABDOUL-AZIZE, S., SELVAKUMAR, S., SADOU, H., BESNARD, P. & KHAN, 455 
N. A. 2014. Ca2+ signaling in taste bud cells and spontaneous preference for 456 
fat: unresolved roles of CD36 and GPR120. Biochimie, 96, 8-13. 457 
ALBERTI, K. G. & ZIMMET, P. Z. 2014. Diabetes: a look to the future. Lancet 458 
Diabetes Endocrinol, 2, e1-2. 459 
ARAKI, T., HIRAYAMA, M., HIROI, S. & KAKU, K. 2012. GPR40-induced insulin 460 
secretion by the novel agonist TAK-875: first clinical findings in patients with 461 
type 2 diabetes. Diabetes Obes Metab, 14, 271-8. 462 
BAILEY, C. J. 2012. Could FFAR1 assist insulin secretion in type 2 diabetes? Lancet, 463 
379, 1370-1. 464 
BINDELS, L. B., DEWULF, E. M. & DELZENNE, N. M. 2013. GPR43/FFA2: 465 
physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci, 466 
34, 226-32. 467 
BJURSELL, M., ADMYRE, T., GORANSSON, M., MARLEY, A. E., SMITH, D. 468 
M., OSCARSSON, J. & BOHLOOLY, Y. M. 2011. Improved glucose control 469 
and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a 470 
high-fat diet. Am J Physiol Endocrinol Metab, 300, E211-20. 471 
BRISCOE, C. P., PEAT, A. J., MCKEOWN, S. C., CORBETT, D. F., GOETZ, A. S., 472 
LITTLETON, T. R., MCCOY, D. C., KENAKIN, T. P., ANDREWS, J. L., 473 
AMMALA, C., FORNWALD, J. A., IGNAR, D. M. & JENKINSON, S. 2006. 474 
Pharmacological regulation of insulin secretion in MIN6 cells through the 475 
fatty acid receptor GPR40: identification of agonist and antagonist small 476 
molecules. Br J Pharmacol, 148, 619-28. 477 
BROWN, A. J., GOLDSWORTHY, S. M., BARNES, A. A., EILERT, M. M., 478 
TCHEANG, L., DANIELS, D., MUIR, A. I., WIGGLESWORTH, M. J., 479 
KINGHORN, I., FRASER, N. J., PIKE, N. B., STRUM, J. C., STEPLEWSKI, 480 
K. M., MURDOCK, P. R., HOLDER, J. C., MARSHALL, F. H., SZEKERES, 481 
P. G., WILSON, S., IGNAR, D. M., FOORD, S. M., WISE, A. & DOWELL, 482 
S. J. 2003. The Orphan G protein-coupled receptors GPR41 and GPR43 are 483 
activated by propionate and other short chain carboxylic acids. J Biol Chem, 484 
278, 11312-9. 485 
BROWN, S. P., DRANSFIELD, P. J., VIMOLRATANA, M., JIAO, X., ZHU, L., 486 
PATTAROPONG, V., SUN, Y., LIU, J., LUO, J., ZHANG, J., WONG, S., 487 
ZHUANG, R., GUO, Q., LI, F., MEDINA, J. C., SWAMINATH, G., LIN, D. 488 
C. & HOUZE, J. B. 2012. Discovery of AM-1638: A Potent and Orally 489 
Bioavailable GPR40/FFA1 Full Agonist. ACS Med Chem Lett, 3, 726-30. 490 
BURANT, C. F. 2013. Activation of GPR40 as a therapeutic target for the treatment 491 
of type 2 diabetes. Diabetes Care, 36 Suppl 2, S175-9. 492 
BURANT, C. F., VISWANATHAN, P., MARCINAK, J., CAO, C., VAKILYNEJAD, 493 
M., XIE, B. & LEIFKE, E. 2012. TAK-875 versus placebo or glimepiride in 494 
type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-495 
controlled trial. Lancet, 379, 1403-11. 496 
CANI, P. D., EVERARD, A. & DUPARC, T. 2013. Gut microbiota, enteroendocrine 497 
functions and metabolism. Curr Opin Pharmacol, 13, 935-40. 498 
CARTONI, C., YASUMATSU, K., OHKURI, T., SHIGEMURA, N., YOSHIDA, R., 499 
GODINOT, N., LE COUTRE, J., NINOMIYA, Y. & DAMAK, S. 2010. Taste 500 
preference for fatty acids is mediated by GPR40 and GPR120. J Neurosci, 30, 501 
8376-82. 502 
CHRISTIANSEN, E., DUE-HANSEN, M. E., URBAN, C., GRUNDMANN, M., 503 
SCHMIDT, J., HANSEN, S. V., HUDSON, B. D., ZAIBI, M., MARKUSSEN, 504 
S. B., HAGESAETHER, E., MILLIGAN, G., CAWTHORNE, M. A., 505 
KOSTENIS, E., KASSACK, M. U. & ULVEN, T. 2013a. Discovery of a 506 
potent and selective free fatty acid receptor 1 agonist with low lipophilicity 507 
and high oral bioavailability. J Med Chem, 56, 982-92. 508 
CHRISTIANSEN, E., DUE-HANSEN, M. E., URBAN, C., GRUNDMANN, M., 509 
SCHRODER, R., HUDSON, B. D., MILLIGAN, G., CAWTHORNE, M. A., 510 
KOSTENIS, E., KASSACK, M. U. & ULVEN, T. 2012. Free fatty acid 511 
receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers 512 
lipophilicity and improves ADME properties. J Med Chem, 55, 6624-8. 513 
CHRISTIANSEN, E., DUE-HANSEN, M. E., URBAN, C., MERTEN, N., 514 
PFLEIDERER, M., KARLSEN, K. K., RASMUSSEN, S. S., 515 
STEENSGAARD, M., HAMACHER, A., SCHMIDT, J., DREWKE, C., 516 
PETERSEN, R. K., KRISTIANSEN, K., ULLRICH, S., KOSTENIS, E., 517 
KASSACK, M. U. & ULVEN, T. 2010. Structure-Activity Study of 518 
Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist 519 
TUG-469. ACS Med Chem Lett, 1, 345-9. 520 
CHRISTIANSEN, E., HANSEN, S. V., URBAN, C., HUDSON, B. D., WARGENT, 521 
E. T., GRUNDMANN, M., JENKINS, L., ZAIBI, M., STOCKER, C. J., 522 
ULLRICH, S., KOSTENIS, E., KASSACK, M. U., MILLIGAN, G., 523 
CAWTHORNE, M. A. & ULVEN, T. 2013b. Discovery of TUG-770: A 524 
Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for 525 
Treatment of Type 2 Diabetes. ACS Med Chem Lett, 4, 441-445. 526 
CHRISTIANSEN, E., URBAN, C., GRUNDMANN, M., DUE-HANSEN, M. E., 527 
HAGESAETHER, E., SCHMIDT, J., PARDO, L., ULLRICH, S., KOSTENIS, 528 
E., KASSACK, M. & ULVEN, T. 2011. Identification of a potent and 529 
selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable 530 
physicochemical and in vitro ADME properties. J Med Chem, 54, 6691-703. 531 
CHRISTIANSEN, E., URBAN, C., MERTEN, N., LIEBSCHER, K., KARLSEN, K. 532 
K., HAMACHER, A., SPINRATH, A., BOND, A. D., DREWKE, C., 533 
ULLRICH, S., KASSACK, M. U., KOSTENIS, E. & ULVEN, T. 2008. 534 
Discovery of potent and selective agonists for the free fatty acid receptor 1 535 
(FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med 536 
Chem, 51, 7061-4. 537 
CINTRA, D. E., ROPELLE, E. R., MORAES, J. C., PAULI, J. R., MORARI, J., 538 
SOUZA, C. T., GRIMALDI, R., STAHL, M., CARVALHEIRA, J. B., SAAD, 539 
M. J. & VELLOSO, L. A. 2012. Unsaturated fatty acids revert diet-induced 540 
hypothalamic inflammation in obesity. PLoS One, 7, e30571. 541 
CORNALL, L. M., MATHAI, M. L., HRYCIW, D. H. & MCAINCH, A. J. 2013. 542 
The therapeutic potential of GPR43: a novel role in modulating metabolic 543 
health. Cell Mol Life Sci, 70, 4759-70. 544 
CORNALL, L. M., MATHAI, M. L., HRYCIW, D. H. & MCAINCH, A. J. 2014. 545 
GPR120 agonism as a countermeasure against metabolic diseases. Drug 546 
Discov Today, 19, 670-679. 547 
DEFOSSA, E. & WAGNER, M. 2014. Recent developments in the discovery of 548 
FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus. 549 
Bioorg Med Chem Lett, 24, 2991-3000. 550 
DEL GUERRA, S., BUGLIANI, M., D'ALEO, V., DEL PRATO, S., BOGGI, U., 551 
MOSCA, F., FILIPPONI, F. & LUPI, R. 2010. G-protein-coupled receptor 40 552 
(GPR40) expression and its regulation in human pancreatic islets: the role of 553 
type 2 diabetes and fatty acids. Nutr Metab Cardiovasc Dis, 20, 22-5. 554 
EDFALK, S., STENEBERG, P. & EDLUND, H. 2008. Gpr40 is expressed in 555 
enteroendocrine cells and mediates free fatty acid stimulation of incretin 556 
secretion. Diabetes, 57, 2280-7. 557 
ENGELSTOFT, M. S., PARK, W. M., SAKATA, I., KRISTENSEN, L. V., HUSTED, 558 
A. S., OSBORNE-LAWRENCE, S., PIPER, P. K., WALKER, A. K., 559 
PEDERSEN, M. H., NOHR, M. K., PAN, J., SINZ, C. J., CARRINGTON, P. 560 
E., AKIYAMA, T. E., JONES, R. M., TANG, C., AHMED, K., 561 
OFFERMANNS, S., EGEROD, K. L., ZIGMAN, J. M. & SCHWARTZ, T. W. 562 
2013. Seven transmembrane G protein-coupled receptor repertoire of gastric 563 
ghrelin cells. Mol Metab, 2, 376-92. 564 
FERDAOUSSI, M., BERGERON, V., ZARROUKI, B., KOLIC, J., CANTLEY, J., 565 
FIELITZ, J., OLSON, E. N., PRENTKI, M., BIDEN, T., MACDONALD, P. 566 
E. & POITOUT, V. 2012. G protein-coupled receptor (GPR)40-dependent 567 
potentiation of insulin secretion in mouse islets is mediated by protein kinase 568 
D1. Diabetologia, 55, 2682-92. 569 
FLODGREN, E., OLDE, B., MEIDUTE-ABARAVICIENE, S., WINZELL, M. S., 570 
AHREN, B. & SALEHI, A. 2007. GPR40 is expressed in glucagon producing 571 
cells and affects glucagon secretion. Biochem Biophys Res Commun, 354, 240-572 
5. 573 
FONTES, G., ZARROUKI, B., HAGMAN, D. K., LATOUR, M. G., SEMACHE, M., 574 
ROSKENS, V., MOORE, P. C., PRENTKI, M., RHODES, C. J., JETTON, T. 575 
L. & POITOUT, V. 2010. Glucolipotoxicity age-dependently impairs beta cell 576 
function in rats despite a marked increase in beta cell mass. Diabetologia, 53, 577 
2369-79. 578 
GILBERTSON, T. A. & KHAN, N. A. 2014. Cell signaling mechanisms of oro-579 
gustatory detection of dietary fat: advances and challenges. Prog Lipid Res, 53, 580 
82-92. 581 
GONG, Z., YOSHIMURA, M., AIZAWA, S., KUROTANI, R., ZIGMAN, J. M., 582 
SAKAI, T. & SAKATA, I. 2014. G protein-coupled receptor 120 signaling 583 
regulates ghrelin secretion in vivo and in vitro. Am J Physiol Endocrinol 584 
Metab, 306, E28-35. 585 
HALDER, S., KUMAR, S. & SHARMA, R. 2013. The therapeutic potential of 586 
GPR120: a patent review. Expert Opin Ther Pat, 23, 1581-90. 587 
HIRASAWA, A., ITSUBO, C., SADAKANE, K., HARA, T., SHINAGAWA, S., 588 
KOGA, H., NOSE, H., KOSHIMIZU, T. A. & TSUJIMOTO, G. 2008. 589 
Production and characterization of a monoclonal antibody against GPR40 590 
(FFAR1; free fatty acid receptor 1). Biochem Biophys Res Commun, 365, 22-8. 591 
HIRASAWA, A., TSUMAYA, K., AWAJI, T., KATSUMA, S., ADACHI, T., 592 
YAMADA, M., SUGIMOTO, Y., MIYAZAKI, S. & TSUJIMOTO, G. 2005. 593 
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through 594 
GPR120. Nat Med, 11, 90-4. 595 
HOLLIDAY, N. D., WATSON, S. J. & BROWN, A. J. 2011. Drug discovery 596 
opportunities and challenges at g protein coupled receptors for long chain free 597 
Fatty acids. Front Endocrinol (Lausanne), 2, 112. 598 
HOUZE, J. B., ZHU, L., SUN, Y., AKERMAN, M., QIU, W., ZHANG, A. J., 599 
SHARMA, R., SCHMITT, M., WANG, Y., LIU, J., LIU, J., MEDINA, J. C., 600 
REAGAN, J. D., LUO, J., TONN, G., ZHANG, J., LU, J. Y., CHEN, M., 601 
LOPEZ, E., NGUYEN, K., YANG, L., TANG, L., TIAN, H., 602 
SHUTTLEWORTH, S. J. & LIN, D. C. 2012. AMG 837: a potent, orally 603 
bioavailable GPR40 agonist. Bioorg Med Chem Lett, 22, 1267-70. 604 
HUDSON, B. D., CHRISTIANSEN, E., MURDOCH, H., JENKINS, L., HANSEN, 605 
A. H., MADSEN, O., ULVEN, T. & MILLIGAN, G. 2014a. Complex 606 
pharmacology of novel allosteric free Fatty Acid 3 receptor ligands. Mol 607 
Pharmacol, 86, 200-10. 608 
HUDSON, B. D., CHRISTIANSEN, E., TIKHONOVA, I. G., GRUNDMANN, M., 609 
KOSTENIS, E., ADAMS, D. R., ULVEN, T. & MILLIGAN, G. 2012a. 610 
Chemically engineering ligand selectivity at the free fatty acid receptor 2 611 
based on pharmacological variation between species orthologs. FASEB J, 26, 612 
4951-65. 613 
HUDSON, B. D., DUE-HANSEN, M. E., CHRISTIANSEN, E., HANSEN, A. M., 614 
MACKENZIE, A. E., MURDOCH, H., PANDEY, S. K., WARD, R. J., 615 
MARQUEZ, R., TIKHONOVA, I. G., ULVEN, T. & MILLIGAN, G. 2013a. 616 
Defining the molecular basis for the first potent and selective orthosteric 617 
agonists of the FFA2 free fatty acid receptor. J Biol Chem, 288, 17296-312. 618 
HUDSON, B. D., SHIMPUKADE, B., MACKENZIE, A. E., BUTCHER, A. J., 619 
PEDIANI, J. D., CHRISTIANSEN, E., HEATHCOTE, H., TOBIN, A. B., 620 
ULVEN, T. & MILLIGAN, G. 2013b. The pharmacology of TUG-891, a 621 
potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), 622 
demonstrates both potential opportunity and possible challenges to therapeutic 623 
agonism. Mol Pharmacol, 84, 710-25. 624 
HUDSON, B. D., SHIMPUKADE, B., MILLIGAN, G. & ULVEN, T. 2014b. The 625 
Molecular Basis of Ligand Interaction at Free Fatty Acid Receptor 4 626 
(FFA4/GPR120). J Biol Chem, 289, 20345-20358. 627 
HUDSON, B. D., TIKHONOVA, I. G., PANDEY, S. K., ULVEN, T. & MILLIGAN, 628 
G. 2012b. Extracellular ionic locks determine variation in constitutive activity 629 
and ligand potency between species orthologs of the free fatty acid receptors 630 
FFA2 and FFA3. J Biol Chem, 287, 41195-209. 631 
ICHIMURA, A., HIRASAWA, A., POULAIN-GODEFROY, O., BONNEFOND, A., 632 
HARA, T., YENGO, L., KIMURA, I., LELOIRE, A., LIU, N., IIDA, K., 633 
CHOQUET, H., BESNARD, P., LECOEUR, C., VIVEQUIN, S., 634 
AYUKAWA, K., TAKEUCHI, M., OZAWA, K., TAUBER, M., MAFFEIS, 635 
C., MORANDI, A., BUZZETTI, R., ELLIOTT, P., POUTA, A., JARVELIN, 636 
M. R., KORNER, A., KIESS, W., PIGEYRE, M., CAIAZZO, R., VAN HUL, 637 
W., VAN GAAL, L., HORBER, F., BALKAU, B., LEVY-MARCHAL, C., 638 
ROUSKAS, K., KOUVATSI, A., HEBEBRAND, J., HINNEY, A., 639 
SCHERAG, A., PATTOU, F., MEYRE, D., KOSHIMIZU, T. A., 640 
WOLOWCZUK, I., TSUJIMOTO, G. & FROGUEL, P. 2012. Dysfunction of 641 
lipid sensor GPR120 leads to obesity in both mouse and human. Nature, 483, 642 
350-4. 643 
ITO, R., TSUJIHATA, Y., MATSUDA-NAGASUMI, K., MORI, I., NEGORO, N. & 644 
TAKEUCHI, K. 2013. TAK-875, a GPR40/FFAR1 agonist, in combination 645 
with metformin prevents progression of diabetes and beta-cell dysfunction in 646 
Zucker diabetic fatty rats. Br J Pharmacol, 170, 568-80. 647 
ITOH, Y., KAWAMATA, Y., HARADA, M., KOBAYASHI, M., FUJII, R., 648 
FUKUSUMI, S., OGI, K., HOSOYA, M., TANAKA, Y., UEJIMA, H., 649 
TANAKA, H., MARUYAMA, M., SATOH, R., OKUBO, S., KIZAWA, H., 650 
KOMATSU, H., MATSUMURA, F., NOGUCHI, Y., SHINOHARA, T., 651 
HINUMA, S., FUJISAWA, Y. & FUJINO, M. 2003. Free fatty acids regulate 652 
insulin secretion from pancreatic beta cells through GPR40. Nature, 422, 173-653 
6. 654 
KEBEDE, M., FERDAOUSSI, M., MANCINI, A., ALQUIER, T., KULKARNI, R. 655 
N., WALKER, M. D. & POITOUT, V. 2012. Glucose activates free fatty acid 656 
receptor 1 gene transcription via phosphatidylinositol-3-kinase-dependent O-657 
GlcNAcylation of pancreas-duodenum homeobox-1. Proc Natl Acad Sci U S A, 658 
109, 2376-81. 659 
KIMURA, I., OZAWA, K., INOUE, D., IMAMURA, T., KIMURA, K., MAEDA, T., 660 
TERASAWA, K., KASHIHARA, D., HIRANO, K., TANI, T., TAKAHASHI, 661 
T., MIYAUCHI, S., SHIOI, G., INOUE, H. & TSUJIMOTO, G. 2013. The 662 
gut microbiota suppresses insulin-mediated fat accumulation via the short-663 
chain fatty acid receptor GPR43. Nat Commun, 4, 1829. 664 
LAN, H., HOOS, L. M., LIU, L., TETZLOFF, G., HU, W., ABBONDANZO, S. J., 665 
VASSILEVA, G., GUSTAFSON, E. L., HEDRICK, J. A. & DAVIS, H. R. 666 
2008. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-667 
induced metabolic disease. Diabetes, 57, 2999-3006. 668 
LATOUR, M. G., ALQUIER, T., OSEID, E., TREMBLAY, C., JETTON, T. L., LUO, 669 
J., LIN, D. C. & POITOUT, V. 2007. GPR40 is necessary but not sufficient 670 
for fatty acid stimulation of insulin secretion in vivo. Diabetes, 56, 1087-94. 671 
LE POUL, E., LOISON, C., STRUYF, S., SPRINGAEL, J. Y., LANNOY, V., 672 
DECOBECQ, M. E., BREZILLON, S., DUPRIEZ, V., VASSART, G., VAN 673 
DAMME, J., PARMENTIER, M. & DETHEUX, M. 2003. Functional 674 
characterization of human receptors for short chain fatty acids and their role in 675 
polymorphonuclear cell activation. J Biol Chem, 278, 25481-9. 676 
LEIFKE, E., NAIK, H., WU, J., VISWANATHAN, P., DEMANNO, D., KIPNES, M. 677 
& VAKILYNEJAD, M. 2012. A multiple-ascending-dose study to evaluate 678 
safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, 679 
TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther, 92, 29-39. 680 
LI, X., YU, Y. & FUNK, C. D. 2013. Cyclooxygenase-2 induction in macrophages is 681 
modulated by docosahexaenoic acid via interactions with free fatty acid 682 
receptor 4 (FFA4). FASEB J, 27, 4987-97. 683 
LIN, D. C., GUO, Q., LUO, J., ZHANG, J., NGUYEN, K., CHEN, M., TRAN, T., 684 
DRANSFIELD, P. J., BROWN, S. P., HOUZE, J., VIMOLRATANA, M., 685 
JIAO, X. Y., WANG, Y., BIRDSALL, N. J. & SWAMINATH, G. 2012a. 686 
Identification and pharmacological characterization of multiple allosteric 687 
binding sites on the free fatty acid 1 receptor. Mol Pharmacol, 82, 843-59. 688 
LIN, H. V., FRASSETTO, A., KOWALIK, E. J., JR., NAWROCKI, A. R., LU, M. 689 
M., KOSINSKI, J. R., HUBERT, J. A., SZETO, D., YAO, X., FORREST, G. 690 
& MARSH, D. J. 2012b. Butyrate and propionate protect against diet-induced 691 
obesity and regulate gut hormones via free fatty acid receptor 3-independent 692 
mechanisms. PLoS One, 7, e35240. 693 
LIOU, A. P., LU, X., SEI, Y., ZHAO, X., PECHHOLD, S., CARRERO, R. J., 694 
RAYBOULD, H. E. & WANK, S. 2011. The G-protein-coupled receptor 695 
GPR40 directly mediates long-chain fatty acid-induced secretion of 696 
cholecystokinin. Gastroenterology, 140, 903-12. 697 
LUO, J., SWAMINATH, G., BROWN, S. P., ZHANG, J., GUO, Q., CHEN, M., 698 
NGUYEN, K., TRAN, T., MIAO, L., DRANSFIELD, P. J., 699 
VIMOLRATANA, M., HOUZE, J. B., WONG, S., TOTEVA, M., SHAN, B., 700 
LI, F., ZHUANG, R. & LIN, D. C. 2012. A potent class of GPR40 full 701 
agonists engages the enteroinsular axis to promote glucose control in rodents. 702 
PLoS One, 7, e46300. 703 
MA, D., TAO, B., WARASHINA, S., KOTANI, S., LU, L., KAPLAMADZHIEV, D. 704 
B., MORI, Y., TONCHEV, A. B. & YAMASHIMA, T. 2007. Expression of 705 
free fatty acid receptor GPR40 in the central nervous system of adult monkeys. 706 
Neurosci Res, 58, 394-401. 707 
MAJUMDAR, S. K. & INZUCCHI, S. E. 2013. Investigational anti-hyperglycemic 708 
agents: the future of type 2 diabetes therapy? Endocrine, 44, 47-58. 709 
MANCINI, A. D. & POITOUT, V. 2013. The fatty acid receptor FFA1/GPR40 a 710 
decade later: how much do we know? Trends Endocrinol Metab, 24, 398-407. 711 
MCCARTHY, M. I. 2010. Genomics, type 2 diabetes, and obesity. N Engl J Med, 363, 712 
2339-50. 713 
NAGASUMI, K., ESAKI, R., IWACHIDOW, K., YASUHARA, Y., OGI, K., 714 
TANAKA, H., NAKATA, M., YANO, T., SHIMAKAWA, K., TAKETOMI, 715 
S., TAKEUCHI, K., ODAKA, H. & KAISHO, Y. 2009. Overexpression of 716 
GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion 717 
and improves glucose tolerance in normal and diabetic mice. Diabetes, 58, 718 
1067-76. 719 
NAIK, H., VAKILYNEJAD, M., WU, J., VISWANATHAN, P., DOTE, N., 720 
HIGUCHI, T. & LEIFKE, E. 2012. Safety, tolerability, pharmacokinetics, and 721 
pharmacodynamic properties of the GPR40 agonist TAK-875: results from a 722 
double-blind, placebo-controlled single oral dose rising study in healthy 723 
volunteers. J Clin Pharmacol, 52, 1007-16. 724 
NAKAMOTO, K., NISHINAKA, T., SATO, N., MANKURA, M., KOYAMA, Y., 725 
KASUYA, F. & TOKUYAMA, S. 2013. Hypothalamic GPR40 signaling 726 
activated by free long chain fatty acids suppresses CFA-induced inflammatory 727 
chronic pain. PLoS One, 8, e81563. 728 
NAKASHIMA, R., YANO, T., OGAWA, J., TANAKA, N., TODA, N., YOSHIDA, 729 
M., TAKANO, R., INOUE, M., HONDA, T., KUME, S. & MATSUMOTO, 730 
K. 2014. Potentiation of insulin secretion and improvement of glucose 731 
intolerance by combining a novel G protein-coupled receptor 40 agonist DS-732 
1558 with glucagon-like peptide-1 receptor agonists. Eur J Pharmacol, 737C, 733 
194-201. 734 
NILSSON, N. E., KOTARSKY, K., OWMAN, C. & OLDE, B. 2003. Identification 735 
of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by 736 
short-chain fatty acids. Biochem Biophys Res Commun, 303, 1047-52. 737 
NOHR, M. K., PEDERSEN, M. H., GILLE, A., EGEROD, K. L., ENGELSTOFT, M. 738 
S., HUSTED, A. S., SICHLAU, R. M., GRUNDDAL, K. V., POULSEN, S. S., 739 
HAN, S., JONES, R. M., OFFERMANNS, S. & SCHWARTZ, T. W. 2013. 740 
GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in 741 
enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric 742 
leukocytes. Endocrinology, 154, 3552-64. 743 
OFFERMANNS, S. 2014. Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) 744 
receptors. Annu Rev Pharmacol Toxicol, 54, 407-34. 745 
OH, D. Y., TALUKDAR, S., BAE, E. J., IMAMURA, T., MORINAGA, H., FAN, 746 
W., LI, P., LU, W. J., WATKINS, S. M. & OLEFSKY, J. M. 2010. GPR120 is 747 
an omega-3 fatty acid receptor mediating potent anti-inflammatory and 748 
insulin-sensitizing effects. Cell, 142, 687-98. 749 
PAULSEN, S. J., LARSEN, L. K., HANSEN, G., CHELUR, S., LARSEN, P. J. & 750 
VRANG, N. 2014. Expression of the fatty acid receptor GPR120 in the gut of 751 
diet-induced-obese rats and its role in GLP-1 secretion. PLoS One, 9, e88227. 752 
POITOUT, V. & LIN, D. C. 2013. Modulating GPR40: therapeutic promise and 753 
potential in diabetes. Drug Discov Today, 18, 1301-8. 754 
SAMUEL, B. S., SHAITO, A., MOTOIKE, T., REY, F. E., BACKHED, F., 755 
MANCHESTER, J. K., HAMMER, R. E., WILLIAMS, S. C., CROWLEY, J., 756 
YANAGISAWA, M. & GORDON, J. I. 2008. Effects of the gut microbiota on 757 
host adiposity are modulated by the short-chain fatty-acid binding G protein-758 
coupled receptor, Gpr41. Proc Natl Acad Sci U S A, 105, 16767-72. 759 
SCHMIDT, J., SMITH, N. J., CHRISTIANSEN, E., TIKHONOVA, I. G., 760 
GRUNDMANN, M., HUDSON, B. D., WARD, R. J., DREWKE, C., 761 
MILLIGAN, G., KOSTENIS, E. & ULVEN, T. 2011. Selective orthosteric 762 
free fatty acid receptor 2 (FFA2) agonists: identification of the structural and 763 
chemical requirements for selective activation of FFA2 versus FFA3. J Biol 764 
Chem, 286, 10628-40. 765 
SHIMPUKADE, B., HUDSON, B. D., HOVGAARD, C. K., MILLIGAN, G. & 766 
ULVEN, T. 2012. Discovery of a potent and selective GPR120 agonist. J Med 767 
Chem, 55, 4511-5. 768 
SPARKS, S. M., CHEN, G., COLLINS, J. L., DANGER, D., DOCK, S. T., 769 
JAYAWICKREME, C., JENKINSON, S., LAUDEMAN, C., LEESNITZER, 770 
M. A., LIANG, X., MALONEY, P., MCCOY, D. C., MONCOL, D., RASH, 771 
V., RIMELE, T., VULIMIRI, P., WAY, J. M. & ROSS, S. 2014. 772 
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 773 
4 (FFA4/GPR120). Bioorg Med Chem Lett, 24, 3100-3. 774 
STENEBERG, P., RUBINS, N., BARTOOV-SHIFMAN, R., WALKER, M. D. & 775 
EDLUND, H. 2005. The FFA receptor GPR40 links hyperinsulinemia, hepatic 776 
steatosis, and impaired glucose homeostasis in mouse. Cell Metab, 1, 245-58. 777 
STONE, V. M., DHAYAL, S., BROCKLEHURST, K. J., LENAGHAN, C., 778 
SORHEDE WINZELL, M., HAMMAR, M., XU, X., SMITH, D. M. & 779 
MORGAN, N. G. 2014. GPR120 (FFAR4) is preferentially expressed in 780 
pancreatic delta cells and regulates somatostatin secretion from murine islets 781 
of Langerhans. Diabetologia, 57, 1182-91. 782 
SUCKOW, A. T., POLIDORI, D., YAN, W., CHON, S., MA, J. Y., LEONARD, J. & 783 
BRISCOE, C. P. 2014. Alteration of the Glucagon Axis in GPR120 (FFAR4) 784 
Knockout Mice: A ROLE FOR GPR120 IN GLUCAGON SECRETION. J 785 
Biol Chem, 289, 15751-15763. 786 
TAKANO, R., YOSHIDA, M., INOUE, M., HONDA, T., NAKASHIMA, R., 787 
MATSUMOTO, K., YANO, T., OGATA, T., WATANABE, N. & TODA, N. 788 
2014. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 789 
agonists. Bioorg Med Chem Lett, 24, 2949-53. 790 
TANAKA, H., YOSHIDA, S., MINOURA, H., NEGORO, K., SHIMAYA, A., 791 
SHIMOKAWA, T. & SHIBASAKI, M. 2014. Novel GPR40 agonist 792 
AS2575959 exhibits glucose metabolism improvement and synergistic effect 793 
with sitagliptin on insulin and incretin secretion. Life Sci, 94, 115-21. 794 
TANAKA, H., YOSHIDA, S., OSHIMA, H., MINOURA, H., NEGORO, K., 795 
YAMAZAKI, T., SAKUDA, S., IWASAKI, F., MATSUI, T. & SHIBASAKI, 796 
M. 2013. Chronic treatment with novel GPR40 agonists improve whole-body 797 
glucose metabolism based on the glucose-dependent insulin secretion. J 798 
Pharmacol Exp Ther, 346, 443-52. 799 
TANEERA, J., LANG, S., SHARMA, A., FADISTA, J., ZHOU, Y., AHLQVIST, E., 800 
JONSSON, A., LYSSENKO, V., VIKMAN, P., HANSSON, O., PARIKH, H., 801 
KORSGREN, O., SONI, A., KRUS, U., ZHANG, E., JING, X. J., 802 
ESGUERRA, J. L., WOLLHEIM, C. B., SALEHI, A., ROSENGREN, A., 803 
RENSTROM, E. & GROOP, L. 2012. A systems genetics approach identifies 804 
genes and pathways for type 2 diabetes in human islets. Cell Metab, 16, 122-805 
34. 806 
TOLHURST, G., HEFFRON, H., LAM, Y. S., PARKER, H. E., HABIB, A. M., 807 
DIAKOGIANNAKI, E., CAMERON, J., GROSSE, J., REIMANN, F. & 808 
GRIBBLE, F. M. 2012. Short-chain fatty acids stimulate glucagon-like 809 
peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes, 61, 810 
364-71. 811 
TSUJIHATA, Y., ITO, R., SUZUKI, M., HARADA, A., NEGORO, N., YASUMA, 812 
T., MOMOSE, Y. & TAKEUCHI, K. 2011. TAK-875, an orally available G 813 
protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances 814 
glucose-dependent insulin secretion and improves both postprandial and 815 
fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther, 339, 816 
228-37. 817 
ULVEN, T. 2012. Short-chain free fatty acid receptors FFA2/GPR43 and 818 
FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol 819 
(Lausanne), 3, 111. 820 
URBAN, C., HAMACHER, A., PARTKE, H. J., RODEN, M., SCHINNER, S., 821 
CHRISTIANSEN, E., DUE-HANSEN, M. E., ULVEN, T., GOHLKE, H. & 822 
KASSACK, M. U. 2013. In vitro and mouse in vivo characterization of the 823 
potent free fatty acid 1 receptor agonist TUG-469. Naunyn Schmiedebergs 824 
Arch Pharmacol, 386, 1021-30. 825 
WAGNER, R., KAISER, G., GERST, F., CHRISTIANSEN, E., DUE-HANSEN, M. 826 
E., GRUNDMANN, M., MACHICAO, F., PETER, A., KOSTENIS, E., 827 
ULVEN, T., FRITSCHE, A., HARING, H. U. & ULLRICH, S. 2013. 828 
Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of 829 
insulin secretion in humans. Diabetes, 62, 2106-11. 830 
WALKER, C. G., GOFF, L., BLUCK, L. J., GRIFFIN, B. A., JEBB, S. A., 831 
LOVEGROVE, J. A., SANDERS, T. A., FROST, G. S. & GROUP, R. S. 832 
2011. Variation in the FFAR1 gene modifies BMI, body composition and 833 
beta-cell function in overweight subjects: an exploratory analysis. PLoS One, 834 
6, e19146. 835 
WANG, L., ZHAO, Y., GUI, B., FU, R., MA, F., YU, J., QU, P., DONG, L. & 836 
CHEN, C. 2011. Acute stimulation of glucagon secretion by linoleic acid 837 
results from GPR40 activation and [Ca2+]i increase in pancreatic islet 838 
{alpha}-cells. J Endocrinol, 210, 173-9. 839 
WANG, Y., JIAO, X., KAYSER, F., LIU, J., WANG, Z., WANSKA, M., 840 
GREENBERG, J., WEISZMANN, J., GE, H., TIAN, H., WONG, S., 841 
SCHWANDNER, R., LEE, T. & LI, Y. 2010. The first synthetic agonists of 842 
FFA2: Discovery and SAR of phenylacetamides as allosteric modulators. 843 
Bioorg Med Chem Lett, 20, 493-8. 844 
WANG, Y., LIU, J., DRANSFIELD, P. J., ZHU, L., WANG, Z., DU, X., JIAO, X., 845 
SU, Y., LI, A.-R., BROWN, S. P., KASPARIAN, A., VIMOLRATANA, M., 846 
YU, M., PATTAROPONG, V., HOUZE, J. B., SWAMINATH, G., TRAN, T., 847 
NGUYEN, K., GUO, Q., ZHANG, J., ZHUANG, R., LI, F., MIAO, L., 848 
BARTBERGER, M. D., CORRELL, T. L., CHOW, D., WONG, S., LUO, J., 849 
LIN, D. C. H. & MEDINA, J. C. 2013. Discovery and Optimization of Potent 850 
GPR40 Full Agonists Containing Tricyclic Spirocycles. ACS Medicinal 851 
Chemistry Letters, 4, 551-555. 852 
WELLHAUSER, L. & BELSHAM, D. D. 2014. Activation of the omega-3 fatty acid 853 
receptor GPR120 mediates anti-inflammatory actions in immortalized 854 
hypothalamic neurons. J Neuroinflammation, 11, 60. 855 
WU, P., YANG, L. & SHEN, X. 2010. The relationship between GPR40 and 856 
lipotoxicity of the pancreatic beta-cells as well as the effect of pioglitazone. 857 
Biochem Biophys Res Commun, 403, 36-9. 858 
YASHIRO, H., TSUJIHATA, Y., TAKEUCHI, K., HAZAMA, M., JOHNSON, P. R. 859 
& RORSMAN, P. 2012. The effects of TAK-875, a selective G protein-860 
coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion 861 
in isolated rat and human islets. J Pharmacol Exp Ther, 340, 483-9. 862 
ZAIBI, M. S., STOCKER, C. J., O'DOWD, J., DAVIES, A., BELLAHCENE, M., 863 
CAWTHORNE, M. A., BROWN, A. J., SMITH, D. M. & ARCH, J. R. 2010. 864 
Roles of GPR41 and GPR43 in leptin secretory responses of murine 865 
adipocytes to short chain fatty acids. FEBS Lett, 584, 2381-6. 866 
ZHANG, Y., XU, M., ZHANG, S., YAN, L., YANG, C., LU, W., LI, Y. & CHENG, 867 
H. 2007. The role of G protein-coupled receptor 40 in lipoapoptosis in mouse 868 
beta-cell line NIT-1. J Mol Endocrinol, 38, 651-61. 869 
 870 
 871 
 872 
 873 
 874 
 875 
 876 
 877 
 878 
 879 
 880 
 881 
 882 
 883 
 884 
 885 
 886 
 887 
 888 
 889 
 890 
 891 
 892 
Table 1: FFA receptor agonists for the treatment of T2D 893 
Table 1 illustrates the most commonly described natural and synthetic ligands for 894 
FFA1-4.  The current clinical status of these synthetic agonists for the treatment of 895 
T2D is also described.  896 
 897 
FFA 
Receptor 
Agonists Metabolic Effects Clinical Trial Status 
FFA1 Natural Ligands: 
palmitic acid, oleic 
acid, linoleic acid 
Synthetic ligands: 
GW9508, TAK-
875/Fasiglifam, 
AMG-837, AM-
1638, AM-5262, 
LY2881835, JTT-
851, P11187, 
TUG-469, TUG-
424, TUG-770, 
AS2575959, DS-
1558 
Improved fasting 
hypoglycaemia and glucose 
tolerance in diabetic animal 
models 
 
Increased GSIS 
 
Increased incretin release 
(full agonists: AM-1638, 
AM-5262, LY2881835) 
 
No associated 
hypoglycaemia in 
normoglycaemic rats 
 
 
TAK-875/Fasiglifam (Takeda): 
Phase I/II trials showed reduced 
blood glucose levels, increased 
insulin levels, 1.2-1.4% reduction 
in HbA1c levels with no associated 
weight gain/hypoglycaemia in 
T2D patients. Removed from 
Phase III trials due to potential 
liver toxicity 
AMG-837 (Amgen) and 
LY2881835 (Eli Lilly): removed 
from Phase I trials due to toxicity 
JTT-851 (Japan Tobacco): 
currently in Phase II trials 
P11187(Piramal): currently in 
Phase I trials 
FFA2 Natural ligands: 
acetate (preferred), 
propionate, 
butyrate 
Synthetic ligands: 
AMG7703/4-
CMTB, Euroscreen 
compounds, 
compounds 1 and 2  
Improved glucose uptake 
 
Decreased colon 
motility/contractility 
 
Increased GLP-1 secretion 
 
Inhibition of leukocyte 
activation 
 
 
No agonists currently in clinical 
trials 
FFA3 Natural ligands: 
propionate 
(preferred), 
butyrate, acetate 
Synthetic ligands: 
Arena 
Pharmaceuticals 
series 
Increased GLP-1 secretion 
 
 
No agonists currently in clinical 
trials 
FFA4 Natural ligands: 
alpha-linolenic 
acid (αLA), 
docosahexanoic 
acid (DHA) 
Synthetic ligands: 
GW9508, NCG21, 
NCG46, TUG-891 
Protection against diet-
induced obesity 
 
Improved insulin sensitivity 
and glycaemic control 
 
Increased GLP-1 release 
 
Increased insulin secretion 
(largely attributed to GLP-1 
release) 
 
 
Reduced inflammation 
 
 
 
No compounds currently in clinical 
trials although a number of 
companies have patented FFA4 
agonists for the treatment of T2D 
(Banyu Pharmaceutical, 
Metabolex, Kindex Therapeutics, 
Pharma Frontier)  
 898 
Figure 1: The biological effects of FFA receptors 899 
 900 
Dietary FFAs, such as ω-3 fatty acids from fish oils and SCFAs derived from the 901 
fermentation of dietary fibre, have profound effects on metabolic and inflammatory 902 
processes associated with obesity and T2D. These effects have, at least in part, been 903 
attributed to the activation of Free Fatty Acid receptors (FFA1-4), leading to a great 904 
deal of interest in the development of synthetic FFA receptor agonists for the 905 
treatment of metabolic disease. Agonism of the long chain FFA receptor FFA1, the 906 
most fully characterised of these receptors, improves glucose-stimulated insulin 907 
secretion from the pancreas. Additionally, full agonists of this receptor increase 908 
incretin release from the gut, thereby indirectly increasing pancreatic insulin secretion, 909 
as well as improving systemic insulin sensitivity and promoting satiety. Agonism of 910 
another long chain FFA receptor, FFA4, is associated with incretin release from the 911 
gut, as well as an anti-inflammatory effect on macrophages that, in turn, may improve 912 
systemic insulin sensitivity. In the pancreas, FFA4 is associated with reduced cell 913 
apoptosis and FFA4 has recently been detected in alpha and delta cells and regulates 914 
glucagon and somatostatin release respectively. Both FFA1 and FFA4 have been 915 
detected in taste buds although the full implications of this in relation to obesity 916 
remains to be determined. The SCFA receptors, FFA2/FFA3, have recently been 917 
linked with the beneficial metabolic effects associated probiotics within the gut. Both 918 
receptors have been linked with incretin release from enteroendocrine cells, as well as 919 
both systemic anti- and pro-inflammatory effects. However, due to conflicting results 920 
using receptor-specific knock out models and a limited selection of pharmacological 921 
tools, more work is required to elucidate the physiological effects of FFA2 and FFA3 922 
agonism.       923 
 924 
Figure 2: Representative Free Fatty Acid receptor agonists 925 
 926 
A number of academic and industrial drug programmes are aimed at developing FFA 927 
receptor agonists for the treatment of T2D.  Figure 2 illustrates a representative 928 
selection of the current range of synthetic agonists that have so far been developed for 929 
these receptors. 930 
 931 
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